SCHEMBL6944659

SCHEMBL6944659

O=C(O)C=CSc1ccc(F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
MAPT P10636 5/20 0.47
LMNA P02545 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
PLIN1 O60240 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
PLIN5 Q00G26 1/20 0.47
ABHD5 Q8WTS1 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
MDM2 Q00987 1/20 0.43
HSD11B1 P28845 1/20 0.39
GAA P10253 1/20 0.39
CYP2C19 P33261 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944654 1.00 ALDH1A1 (0.47) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL600479 0.81 ALDH1A1 (0.68) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL9330897 0.81 ALDH1A1 (0.68) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL600478 0.81 ALDH1A1 (0.68) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL20697998 0.80 MAPT (0.47) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL6948401 0.80 ALDH1A1 (0.67) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL6947763 0.80 MAPT (0.62) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL22701981 0.80 ALDH1A1 (0.47) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL6948405 0.80 ALDH1A1 (0.67) ALDH1A1MAPTLMNANPSR1PLIN1
SCHEMBL6947760 0.80 MAPT (0.62) ALDH1A1MAPTLMNANPSR1PLIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642246-B1 Potent ligands for nicotinic acetylcholine receptors (nAChRs). Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's ASTRAZENECA AB (SE) 2003-11-04 US disclosed
EP-1235826-B1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2003-09-03 EP disclosed
EP-1235826-A1 QUINUCLIDINE ACRYLAMIDES AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2001029034-A1 QUINUCLIDINE ACRYLAMIDES ASTRAZENECA AB (SE) 2001-04-26 WO disclosed